Skip to main content
Top
Published in: Gastric Cancer 4/2023

10-04-2023 | Gastric Cancer | Original Article

Molecular profile of poorly cohesive gastric carcinoma with special reference to survival

Authors: Yusuke Koseki, Keiichi Hatakeyama, Masanori Terashima, Takeshi Nagashima, Kenichi Urakami, Keiichi Ohshima, Daisuke Aizawa, Takashi Sugino, Kenichiro Furukawa, Keiichi Fujiya, Yutaka Tanizawa, Etsuro Bando, Yukiyasu Okamura, Yasuto Akiyama, Ken Yamaguchi

Published in: Gastric Cancer | Issue 4/2023

Login to get access

Abstract

Background

Patients with poorly cohesive gastric carcinoma (PCC) are known to have poor survival. However, detailed molecular biology of PCC has not been elucidated, except for mutations in CDH1 and RHOA. Additionally, the molecular profiles of signet-ring cell carcinoma (SRC) have not been fully investigated. We aimed to investigate the association between molecular profiles and survival in PCC and PCC subtypes.

Methods

The present study included 455 patients with gastric adenocarcinoma underwent radical gastrectomy. Whole-exome sequencing and gene expression profiling were conducted. Patients were classified according to the WHO classification as PCC or non-PCC, with PCC being further classified into SRC, combined, and PCC not-otherwise-specified (NOS). Clinicopathological factors and survival were compared with molecular profiles.

Results

Of the patients, 159 were classified with PCC, while 296 were classified with non-PCC. Among PCC, 44 were classified with SRC, 64 with combined, and 51 with PCC-NOS. Mutations in CDH1 and RHOA were remarkably more frequent in PCC than in non-PCC. PCC had worse overall survival (OS) and disease-specific survival (DSS) compared to non-PCC. For PCC, the SRC group had good OS and DSS, whereas PCC-NOS classification with CDH1 mutations was associated with extremely poor survival. In the PCC-NOS and combined groups, patients with mutations in the extracellular domain 1 of CDH1 had poor survival.

Conclusions

Our findings suggest that PCC has poorer survival than non-PCC. Accumulation of CDH1 and RHOA mutations are unique profiles in PCC. Among PCC, CDH1 mutations may play a crucial role in the survival of non-SRC PCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Laurén PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer. 1993;71:2926–33.CrossRefPubMed Laurén PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer. 1993;71:2926–33.CrossRefPubMed
3.
go back to reference Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.CrossRefPubMed Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.CrossRefPubMed
4.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
5.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 15th ed. Tokyo: Kanehara Shuppan; 2017. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 15th ed. Tokyo: Kanehara Shuppan; 2017.
6.
go back to reference WHO Classification of Tumours Editorlal Board. WHO classification of tumours. Digestive system tumours. 5th ed. Geneva: World Health Organization; 2019. WHO Classification of Tumours Editorlal Board. WHO classification of tumours. Digestive system tumours. 5th ed. Geneva: World Health Organization; 2019.
7.
go back to reference Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, et al. Is signet-ring cell carcinoma a specific entity among gastric cancers. Gastric Cancer. 2016;19:1027–40.CrossRefPubMed Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, et al. Is signet-ring cell carcinoma a specific entity among gastric cancers. Gastric Cancer. 2016;19:1027–40.CrossRefPubMed
8.
go back to reference Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265:946–53.CrossRefPubMed Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265:946–53.CrossRefPubMed
9.
go back to reference Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, et al. the FREGAT and BIG-RENAPE networks, prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108(10):1225–35.CrossRefPubMed Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, et al. the FREGAT and BIG-RENAPE networks, prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108(10):1225–35.CrossRefPubMed
10.
go back to reference Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genet. 2014;46:573–82.CrossRefPubMed Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genet. 2014;46:573–82.CrossRefPubMed
11.
go back to reference Bencivenga M, Simbolo M, Ciaparrone C, Vicentini C, Torroni L, Piredda ML, et al. Poorly cohesive gastric cancers showing the transcriptomic hallmarks of epithelial-mesenchymal transition behave aggressively. Ann Surg. 2022;276:822–9.CrossRefPubMed Bencivenga M, Simbolo M, Ciaparrone C, Vicentini C, Torroni L, Piredda ML, et al. Poorly cohesive gastric cancers showing the transcriptomic hallmarks of epithelial-mesenchymal transition behave aggressively. Ann Surg. 2022;276:822–9.CrossRefPubMed
12.
go back to reference Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7.CrossRefPubMed Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7.CrossRefPubMed
13.
go back to reference Kwon CH, Kim YK, Lee S, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.CrossRefPubMed Kwon CH, Kim YK, Lee S, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.CrossRefPubMed
14.
go back to reference Bencivenga M, Treppiedi E, Dal Cero M, Torroni L, Verlato G, Iglesias M, et al. The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours. J Surg Oncol. 2020;121:1084–9.CrossRefPubMed Bencivenga M, Treppiedi E, Dal Cero M, Torroni L, Verlato G, Iglesias M, et al. The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours. J Surg Oncol. 2020;121:1084–9.CrossRefPubMed
15.
go back to reference Roviello F, Marano L, Ambrosio MR, Resca L, D’Ignazio A, Petrelli F, et al. Signet ring cell percentage in poorly cohesive gastric cancer patients: a potential novel predictor of survival. Eur J Surg Oncol. 2022;48:561–9.CrossRefPubMed Roviello F, Marano L, Ambrosio MR, Resca L, D’Ignazio A, Petrelli F, et al. Signet ring cell percentage in poorly cohesive gastric cancer patients: a potential novel predictor of survival. Eur J Surg Oncol. 2022;48:561–9.CrossRefPubMed
16.
go back to reference Nakamura K, Eto K, Iwagami S, Ogawa K, Sawayama H, Ishimoto T, Miyamoto Y, Yoshida N, Baba H, et al. Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer. Int J Clin Oncol. 2022;27:512–9.CrossRefPubMed Nakamura K, Eto K, Iwagami S, Ogawa K, Sawayama H, Ishimoto T, Miyamoto Y, Yoshida N, Baba H, et al. Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer. Int J Clin Oncol. 2022;27:512–9.CrossRefPubMed
17.
go back to reference The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef
18.
go back to reference Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.CrossRefPubMed Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.CrossRefPubMed
19.
go back to reference Yamaguchi K, Urakami K, Ohshima K, Mochizuki T, Akiyama Y, Uesaka K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses-the Project HOPE. Biomed Res. 2014;35:407–12.CrossRefPubMed Yamaguchi K, Urakami K, Ohshima K, Mochizuki T, Akiyama Y, Uesaka K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses-the Project HOPE. Biomed Res. 2014;35:407–12.CrossRefPubMed
20.
go back to reference Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al. Japanese Version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111:687–99.CrossRefPubMedPubMedCentral Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al. Japanese Version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111:687–99.CrossRefPubMedPubMedCentral
21.
go back to reference Furukawa K, Hatakeyama K, Terashima M, Nagashima T, Urakami K, Ohshima K, et al. Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE. Gastric Cancer. 2022;25:138–48.CrossRefPubMed Furukawa K, Hatakeyama K, Terashima M, Nagashima T, Urakami K, Ohshima K, et al. Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE. Gastric Cancer. 2022;25:138–48.CrossRefPubMed
22.
go back to reference Ajani JA, In H, Sano T, et al. Stomach. In: Amin MB, editor., et al., AJCC cancer staging manual. 8th ed. New York: Springer-Verlag; 2016. p. 24. Ajani JA, In H, Sano T, et al. Stomach. In: Amin MB, editor., et al., AJCC cancer staging manual. 8th ed. New York: Springer-Verlag; 2016. p. 24.
23.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.CrossRef
24.
go back to reference Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.CrossRefPubMed Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.CrossRefPubMed
25.
go back to reference Kim SK, Kim HJ, Park JL, Heo H, Kim SY, Lee SI, et al. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer. Gastric Cancer. 2020;23:473–82.CrossRefPubMed Kim SK, Kim HJ, Park JL, Heo H, Kim SY, Lee SI, et al. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer. Gastric Cancer. 2020;23:473–82.CrossRefPubMed
26.
go back to reference Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69:18–31.CrossRefPubMed Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69:18–31.CrossRefPubMed
27.
go back to reference Cheng J, He J, Wang S, Zhao Z, Yan H, Guan Q, et al. Biased influences of low tumor purity on mutation detection in cancer. Front Mol Biosci. 2020;7:533196.CrossRefPubMedPubMedCentral Cheng J, He J, Wang S, Zhao Z, Yan H, Guan Q, et al. Biased influences of low tumor purity on mutation detection in cancer. Front Mol Biosci. 2020;7:533196.CrossRefPubMedPubMedCentral
28.
go back to reference Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23:4441–9.CrossRefPubMedPubMedCentral Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23:4441–9.CrossRefPubMedPubMedCentral
29.
go back to reference Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105:159–67.CrossRefPubMed Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105:159–67.CrossRefPubMed
30.
go back to reference Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008;49:459–67.PubMed Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008;49:459–67.PubMed
31.
go back to reference Leckband D, Prakasam A. Mechanism and dynamics of cadherin adhesion. Annu Rev Biomed Eng. 2006;8:259–8732.CrossRefPubMed Leckband D, Prakasam A. Mechanism and dynamics of cadherin adhesion. Annu Rev Biomed Eng. 2006;8:259–8732.CrossRefPubMed
33.
go back to reference Handschuh G, Luber B, Hutzler P, Höfler H, Becker KF. Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences. J Mol Biol. 2001;314:445–54.CrossRefPubMed Handschuh G, Luber B, Hutzler P, Höfler H, Becker KF. Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences. J Mol Biol. 2001;314:445–54.CrossRefPubMed
34.
go back to reference van Beek E, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, et al. Rates of TP53 mutation are significantly elevated in African American patients with gastric cancer. Ann Surg Oncol. 2018;25:2027–33.CrossRefPubMedPubMedCentral van Beek E, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, et al. Rates of TP53 mutation are significantly elevated in African American patients with gastric cancer. Ann Surg Oncol. 2018;25:2027–33.CrossRefPubMedPubMedCentral
35.
go back to reference Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Mol Oncol. 2021;15:2841–67.CrossRefPubMedPubMedCentral Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Mol Oncol. 2021;15:2841–67.CrossRefPubMedPubMedCentral
36.
go back to reference Zhang WH, Zhang SY, Hou QQ, Qin Y, Chen XZ, Zhou ZG, et al. The significance of the CLDN18-ARHGAP fusion gene in gastric cancer: a systematic review and meta-analysis. Front Oncol. 2020;10:1214.CrossRefPubMedPubMedCentral Zhang WH, Zhang SY, Hou QQ, Qin Y, Chen XZ, Zhou ZG, et al. The significance of the CLDN18-ARHGAP fusion gene in gastric cancer: a systematic review and meta-analysis. Front Oncol. 2020;10:1214.CrossRefPubMedPubMedCentral
37.
go back to reference Urakami K, Shimoda Y, Ohshima K, Nagashima T, Serizawa M, Tanabe T, et al. Next generation sequencing approach for detecting 491 fusion genes from human cancer. Biomed Res. 2016;37:51–62.CrossRefPubMed Urakami K, Shimoda Y, Ohshima K, Nagashima T, Serizawa M, Tanabe T, et al. Next generation sequencing approach for detecting 491 fusion genes from human cancer. Biomed Res. 2016;37:51–62.CrossRefPubMed
Metadata
Title
Molecular profile of poorly cohesive gastric carcinoma with special reference to survival
Authors
Yusuke Koseki
Keiichi Hatakeyama
Masanori Terashima
Takeshi Nagashima
Kenichi Urakami
Keiichi Ohshima
Daisuke Aizawa
Takashi Sugino
Kenichiro Furukawa
Keiichi Fujiya
Yutaka Tanizawa
Etsuro Bando
Yukiyasu Okamura
Yasuto Akiyama
Ken Yamaguchi
Publication date
10-04-2023
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 4/2023
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-023-01390-5

Other articles of this Issue 4/2023

Gastric Cancer 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine